Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis

Cynthia Guzzo, Gerald Lazarus, Bernard S. Goffe, H. Irving Katz, Nicholas J. Lowe, Stephanie H. Pincus

Research output: Contribution to journalArticle

Abstract

Background: The biologically active form of vitamin D3, calcitriol, is effective in the treatment of psoriasis but can alter calcium metabolism. Calcipotriene is an analog of calcitriol that has low calcemic activity and aids in clearing psoriasis. Objective: The purpose of this study was to determine the safety of topical therapy with calcipotriene particularly in relation to calcium and bone metabolism. Methods: In a double-blind, randomized, parallel, vehicle-controlled trial, 78 adults with plaque psoriasis were treated twice daily with topical calcipotriene ointment (50 μg/gm, maximum usage, 120 gm per week) or vehicle for 8 weeks. After a screening visit, patients were admitted to the hospital at weeks 0 (baseline), 1, 2, 4, and 8. Blood and urine chemistry analysis included parathyroid hormone, serum calcium, bone-specific alkaline phosphatase, urinary hydroxyproline, and 24 hour urinary calcium excretion. Bone densitometry measures were performed at baseline and week 8. Results: No incidences of calcipotriene treatment-related hypercalcemia, calcium mobilization from bone, or clinically significant changes in bone density were noted during this study. Conclusion: Topical application of up to 120 gm per week of calcipotriene ointment for 8 weeks is safe and effective for plaque psoriasis. There were no adverse effects on calcium and bone metabolism during this 8-week study.

Original languageEnglish (US)
Pages (from-to)429-433
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume34
Issue number3
DOIs
StatePublished - Mar 1996
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis'. Together they form a unique fingerprint.

  • Cite this